logo-loader
viewGenedrive PLC

Genedrive surges as it announces coronavirus testing collaboration

"The integration of Beckman Coulter Life Sciences' and genedrive's technologies produces a formidable workhorse solution," said Beckman Coulter’s Greg Milosevich.

Genedrive PLC -

Genedrive PLC (LON:GDR), the molecular diagnostics company, has entered into a collaboration with Beckman Coulter Life Sciences to speed up coronavirus (COVID-19) testing.

The plan is to fully automate the entire laboratory polymerase chain reaction (PCR) testing process for COVID-19. The two companies are working to combine and validate the Genedrive 96 SARS-CoV-2 Kit on the Biomek i7 automated workstation with saliva samples extracted using Beckman Coulter's RNAdvance viral extraction chemistry.

Once validated, Beckman Coulter estimates that this new turnkey solution could process around 1,000 PCR samples per Biomek installed during a standard eight-hour working day, overseen by a lab technician for the equivalent of half a working day.

Genedrive has already completed an initial evaluation of Beckman Coulter's RNA extraction chemistry to confirm compatibility with the Genedrive 96 SARS-CoV-2 test. Further work is ongoing to validate clinical saliva samples.

Beckman's RNAdvance Viral XP has already been listed as an extraction method for swab samples for use with the Centers for Disease Control's EUA-authorised COVID-19 test in the US Food and Drug Administration’s frequently asked questions (FAQ) on testing for SARS-CoV-2.

In a statement, David Budd, the chief executive officer of genedrive, said it has been the group's focus to work with a “top tier, high throughput lab automation partner” such as Beckman to drive uptake of its testing kits.

“The combination of our ready to use chemistry with robotics and on-board RNA extraction would give laboratories a unique and rapid workflow that can achieve impressive throughput and result turnaround times,” Budd added.

"The integration of Beckman Coulter Life Sciences' and genedrive's technologies produces a formidable workhorse solution for specialised laboratories looking to establish new or next level laboratory automation with labour cost reduction,” said Beckman Coulter’s Greg Milosevich.

“Our ability to fully integrate the RNA extraction process on the Biomek while simultaneously preparing the plates for analysis is a critical step forward in advancing COVID testing workflows,” he added.

Both companies are working to have the ongoing validation completed in around six weeks, with the initial introduction in the USA at an already identified clinical laboratory.

Shares in genedrive were up 15% at 82p in early deals.

Quick facts: Genedrive PLC

Price: 149 GBX

AIM:GDR
Market: AIM
Market Cap: £77.46 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genedrive's David Budd details launch of its unique coronavirus test kits...

Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version...

on 29/5/20

2 min read